Značaj inicijalnih kliničko-laboratorijskih parametara kao prognostičkih faktora kod bolesnika sa COVID-19

  • Biljana Popovska Jovičić University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Ivana Raković University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Aleksandar Pavković University Clinical Center Kragujevac, Department of Radiological Diagnostics
  • Vladan Marković University Clinical Center Kragujevac, Department of Radiological Diagnostics
  • Sara Petrović University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Jagoda Gavrilović University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Predrag Čanović University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Ružica Radojević Marjanović University Clinical Center Kragujevac, Clinic for Infectious Diseases
  • Marko Folić University Clinical Center Kragujevac, Department of Clinical Pharmacology
Keywords: biološki pokazatelji, telesna masa, indeks, covid-19, smrt, bolest, progresija, hematološki testovi, prognoza, sars-cov-2, bolest, indeks težine, lečenje, ishod

Abstract


Background/Aim. Coronavirus disease 2019 (COVID-19) is a predominantly respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this study was to determine whether there were parameters that could predict the development of a severe clinical picture and fatal outcomes in COVID-19 patients. Methods. The study involved 632 patients treated at the Clinic for Infectious Diseases, University Clinical Center Kragujevac, from June 2020 to February 2021. All patients were divided into two groups according to the need for oxygen therapy (Sat 02 < 94 %). Results. Our results showed that high body mass index (BMI) was singled out as a risk factor for the development of a severe clinical picture (BMI, ORadjusted = 1.263; 95% CI = 1.117 – 1.427; p < 0.001). Prothrombin time (ORadjusted = 1.170; 95% CI = 1.004 - 1.364; p = 0.045), as well as low albumin values (ORadjusted = 0.878; 95% CI = 0.804 - 0.958; p = 0.003), had a predictive significance for the development of a severe clinical picture. Factors that were of predictive importance in patients with fatal outcomes were C-reactive protein (CRP) (ORadjusted = 1.010; 95% CI = 1.001 – 1.019; p = 0.031), lactate dehydrogenase (LDH) (ORadjusted = 1.004; 95% CI = 1.001 – 1.006; p = 0.002), and X-ray of the lungs (ORadjusted = 1.394; 95% CI = 1.170 – 1.661; p < 0.001). Conclusion. The study showed that routine, clinical laboratory parameters can be important in the early detection of patients with a potentially severe clinical picture and fatal outcomes. In patients with a mild clinical picture, CRP, LDH, ferritin, and serum albumin levels may timely indicate disease progression. Monitoring these parameters is of essential importance for the timely clinical assessment of patients with COVID-19 and, thus, the prompt application of adequate therapeutic protocols in the treatment of these patients.

References

Dhar Chowdhury S, Oommen AM. Epidemiology of COVID-19. J Dig Endosc 2020; 11(1): 3–7.

Liu J, Xie W, Wang Y, Xiong Y, Chen S, Han J, et al. A com-parative overview of COVID-19, MERS and SARS: Review article. Int J Surg 2020; 81: 1‒8.

Subbarao K, Mahanty S. Respiratory virus infections: under-standing COVID-19. Immunity 2020; 52(6): 905‒9.

Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical char-acteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 2020; 63(5): 706‒11.

Kim SE, Jeong HS, Yu Y, Shin SU, Kim S, Oh TH, et al. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and pre-symptomatic patients. Int J Infect Dis 2020; 95: 441‒3.

Barboza JJ, Chambergo-Michilot D, Velasquez-Sotomayor M, Silva-Rengifo C, Diaz-Arocutipa C, Caballero-Alvarado J, et al. Assess-ment and management of asymptomatic COVID-19 infection: A systematic review. Travel Med Infect Dis 2021; 41: 102058.

Qu J, Chang LK, Tang X, Du Y, Yang X, Liu X, Han P, Xue Y. Clinical characteristics of COVID-19 and its comparison with influenza pneumonia. Acta Clin Belg 2020; 75(5): 348‒56.

Maguire D, Woods M, Richards C, Dolan R, Veitch JW, Sim WMJ, et al. Prognostic factors in patients admitted to an ur-ban teaching hospital with COVID-19 infection. J Transl Med 2020; 18(1): 354.

de Bruin S, Bos LD, van Roon MA, Tuip-de Boer AM, Schuurman AR, Koel-Simmelinck MJA, et al. Amsterdam UMC COVID-19 Biobank Investigators. Clinical features and prognostic factors in Covid-19: A prospective cohort study. EBioMedicine 2021; 67: 103378.

Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experi-mental chest X-ray scoring system for quantifying and moni-toring disease progression. Radiol Med 2020; 125(5): 509‒13.

Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, Wang FS. Characteristics and prognostic factors of disease severity in pa-tients with COVID-19: The Beijing experience. J Autoimmun 2020; 112: 102473.

Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O'Rahilly S, Aveyard P, et al. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a pro-spective, community-based, cohort study. Lancet Diabetes Endocrinol 2021; 9(6): 350‒9.

Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. Obesity (Silver Spring) 2020; 28(6): 1005.

Gao F, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, et al. Obesity Is a Risk Factor for Greater COVID-19 Severity. Di-abetes Care 2020; 43(7): e72‒e74.

Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract 2020; 14(4): 295‒300.

Sisó-Almirall A, Kostov B, Mas-Heredia M, Vilanova-Rotllan S, Sequeira-Aymar E, Sans-Corrales M, et al. Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona. PloS One 2020; 15(8): e0237960.

Huang J, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, et al. Hy-poalbuminemia predicts the outcome of COVID-19 inde-pendent of age and co-morbidity. J Med Virol 2020; 92(10): 2152‒8.

Prins GH, Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. Liver Int 2020; 40(10): 2568.

Fierro NA. COVID-19 and the liver: What do we know after six months of the pandemic? Ann Hepatol 2020; 19(6): 590‒1.

Luo HC, You CY, Lu SW, Fu YQ. Characteristics of coagula-tion alteration in patients with COVID-19. Ann Hematol 2021; 100(1): 45‒52.

Wang L, He WB, Yu XM, Hu DL, Jiang H. Prolonged pro-thrombin time at admission predicts poor clinical outcome in COVID-19 patients. World J Clin Cases 2020; 8(19): 4370‒9.

Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, et al. D-Dimer and Prothrombin Time Are the Significant Indicators of Se-vere COVID-19 and Poor Prognosis. Biomed Res Int 2020; 2020: 6159720.

Ahnach M, Zbiri S, Nejjari S, Ousti F, Elkettani C. C-reactive protein as an early predictor of COVID-19 severity. J Med Bi-ochem 2020; 39(4): 500‒7.

Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP pre-dict the need for mechanical ventilation in COVID-19. J Al-lergy Clin Immunol 2020; 146(1): 128‒36.e4.

Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med 2020; 38(9): 1722‒6.

Chen D, Li X, Song Q, Hu C, Su F, Dai J, et al. Assessment of Hypokalemia and Clinical Characteristics in Patients with Coronavirus Disease 2019 in Wenzhou, China. JAMA Netw Open 2020; 3(6): e2011122.

Alfano G, Ferrari A, Fontana F, Perrone R, Mori G, Ascione E, et al. Hypokalemia in Patients with COVID-19. Clin Exp Neph-rol 2021; 25(4): 401‒9.

Published
2022/11/01
Section
Original Paper